Clinical Edge Journal Scan

Patients with RA remain at higher risk for SARS-CoV-2 infection and severe outcomes


 

Key clinical point: Patients with rheumatoid arthritis (RA) vs. general population remain at a higher risk for SARS-CoV-2 infection and its severe outcomes; although COVID-19 vaccination has reduced severe outcomes, the risk for breakthrough infections is higher among patients with RA, supporting recent recommendations for booster COVID-19 vaccination.

Major finding: Unvaccinated patients with RA vs. general population were at an increased risk for SARS-CoV-2 infection (adjusted hazard ratio [aHR] 1.11; 95% CI 1.00-1.24), COVID-19 hospitalization (aHR 1.62; 95% CI 1.34-1.96), and COVID-19 death (aHR 1.88; 95% CI 1.37-2.60). COVID-19 vaccination reduced disease severity but not the risk for breakthrough infection in patients with RA vs. general population over 9 months of follow-up (aHR1.10; 95% CI, 1.00-1.20).

Study details: Findings are from 2 cohort studies including patients with RA (unvaccinated n = 15,901; vaccinated n = 14,330) and non-RA individuals from general population (unvaccinated n = 1,558,423; vaccinated n = 1,208,659).

Disclosures: This study was supported by the National Institutes of Health and other sources. ZS Wallace declared receiving research support and consulting fees from various sources unrelated to this work.

Source: Li H et al. Risk of COVID-19 among unvaccinated and vaccinated patients with rheumatoid arthritis: A general population study. Arthritis Care Res (Hoboken) . 2022 (Sep 26). Doi: 10.1002/acr.25028

Recommended Reading

Previous endemic coronavirus encounters linked with long COVID
MDedge Rheumatology
Hard-rock mining and other mining work raise RA risk
MDedge Rheumatology
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Rheumatology
Ten-day methotrexate pause after COVID vaccine booster enhances immunity against Omicron variant
MDedge Rheumatology
Increased risk for severe COVID-19 in rheumatoid arthritis and its phenotypic subgroups
MDedge Rheumatology
RA in remission: Subclinical inflammation lower with cs/bDMARDs combination vs. monotherapy
MDedge Rheumatology
Withdrawing methotrexate increased disease activity without affecting remission rates in RA patients at target
MDedge Rheumatology
RA: Increased risk for VTE with JAK inhibitors
MDedge Rheumatology
Suboptimal early RA management predicts difficult-to-treat RA
MDedge Rheumatology
Smoking worsens disease outcomes in RA
MDedge Rheumatology